Xponance Inc. Has $2.59 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Xponance Inc. boosted its position in United Therapeutics Co. (NASDAQ:UTHR) by 9.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,350 shares of the biotechnology company’s stock after acquiring an additional 605 shares during the quarter. Xponance Inc.’s holdings in United Therapeutics were worth $2,593,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. acquired a new position in shares of United Therapeutics during the 4th quarter worth $25,000. Brooklyn Investment Group acquired a new position in United Therapeutics during the third quarter worth about $33,000. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in shares of United Therapeutics during the 4th quarter valued at approximately $131,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Price Performance

Shares of UTHR stock opened at $312.99 on Friday. The stock has a market capitalization of $14.06 billion, a PE ratio of 13.75, a PEG ratio of 0.97 and a beta of 0.64. The business’s 50 day simple moving average is $345.10 and its 200 day simple moving average is $356.99. United Therapeutics Co. has a one year low of $221.53 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same period in the prior year, the firm posted $4.36 EPS. As a group, research analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on UTHR. HC Wainwright restated a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. UBS Group raised their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $388.25.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $356.68, for a total transaction of $3,566,800.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $919,164.36. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares in the company, valued at $1,966,696.56. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 90,255 shares of company stock worth $32,614,521. Company insiders own 11.90% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.